VEA
PRVB

Virtus ETF Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Virtus ETF Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,657
Closed -$763K – 493
2023
Q1 		$763K Buy
31,657
+562
+2% +$7.05K 0.42% 117
2022
Q4 		$329K Buy
+31,095
New +$251K 0.17% 234
2022
Q2 		– Sell
-26,467
Closed -$194K – 493
2022
Q1 		$194K Sell
26,467
-1,563
-6% -$9.35K 0.09% 200
2021
Q4 		$158K Buy
28,030
+4,363
+18% +$27.7K 0.06% 333
2021
Q3 		$151K Sell
23,667
-1,242
-5% -$7.98K 0.07% 338
2021
Q2 		$210K Buy
24,909
+8,751
+54% +$70.6K 0.09% 313
2021
Q1 		$170K Buy
16,158
+280
+2% +$3.94K 0.07% 342
2020
Q4 		$269K Sell
15,878
-5,607
-26% -$84K 0.11% 282
2020
Q3 		$276K Sell
21,485
-2,916
-12% -$36.8K 0.14% 243
2020
Q2 		$344K Sell
24,401
-6,256
-20% -$79K 0.16% 270
2020
Q1 		$282K Sell
30,657
-4,461
-13% -$57.5K 0.12% 235
2019
Q4 		$523K Buy
+35,118
New +$313K 0.09% 200

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Virtus ETF Advisers's PRVB Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 31,657 shares — an estimated $763K sold.

Virtus ETF Advisers first reported a position in PRVB in Q4 2019 and held it in 12 quarters. The position peaked at $763K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 31,657 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $763K.
  • Virtus ETF Advisers first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
  • Virtus ETF Advisers's Provention Bio, Inc. Common Stock position peaked at $763K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.